TransMedics Group (TMDX) has been drawing attention after recent share price swings, with the stock down 5% over the past month and 46% over the past 3 months, despite positive reported revenue and net income growth.

At a share price of $69.43, the stock has seen a sharp loss of 46% based on the 90 day share price return and a 50.07% decline on the 1 year total shareholder return. This suggests recent momentum has faded despite earlier multi year gains.

If this kind of volatility has your attention, it can help to compare TransMedics with other healthcare growth stories and see how they stack up on fundamentals through the Simply Wall St screener for 39 healthcare AI stocks

With TransMedics trading at $69.43 and flagged as having a potential intrinsic discount and a gap to analyst targets, the key question is whether the recent selloff has created value or if the market is already pricing in future growth.

Most Popular Narrative: 41.1% Undervalued

Compared with a narrative fair value of $117.89, the last close at $69.43 implies a wide gap, setting up a valuation story driven by growth, margins and the discount rate used.

Expansion into new organ types (notably kidney) and next-generation product launches (Gen 3 OCS platforms for heart, lung, and liver) are expected to materially grow TransMedics' total addressable market, improve product mix, and support higher average selling prices, benefiting earnings and longer-term net margins.

Curious what kind of revenue runway and margin profile sit behind that gap between price and fair value? The narrative leans on compound growth, a premium future earnings multiple and a specific discount rate to tie it all together.

Result: Fair Value of $117.89 (UNDERVALUED)

However, the story also depends on successful clinical trial outcomes and smooth international expansion, and setbacks on either front could quickly challenge that undervaluation thesis.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

With sentiment split between recent share price weakness and a valuation gap that some investors view as attractive, it makes sense to weigh the evidence yourself and move quickly while the data is fresh. A good place to start is with a closer look at the company's 4 key rewards

Looking for more investment ideas?

If you are serious about building a stronger watchlist, now is the moment to broaden your search and compare other opportunities while this research is still fresh.

• Target dependable compounders by scanning companies that look undervalued on quality metrics through the 49 high quality undervalued stocks.
• Prioritize sleep-at-night holdings by focusing on businesses screened for resilience and lower risk scores using the 64 resilient stocks with low risk scores.
• Get ahead of the crowd by tracking lesser known companies with strong fundamentals via the screener containing 22 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.